Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
10.08
Oct 30 • 3:59 PM ET Dollar change-0.39 Percentage change(-3.72%)
Aftermarket Close
10.03
Aftermarket • 7:59 PM ET Dollar change-0.05 Percentage change(-0.50%)
Oct 29, 9:41 AMNovavax earns $125 million milestone as Sanofi starts Phase 3 influenza-COVID-19 combo trial in Europe using Nuvaxovid
Index
RUT
Market Cap
1.66B
Enterprise Value
1.24B
Income
-247.73M
Sales
413.80M
Book/sh
-1.16
Cash/sh
4.36
Employees
749
IPO
Dec 05, 1995
P/E
-
Forward P/E
-
PEG
-
P/S
4.02
P/B
-
P/C
2.31
P/FCF
-
EV/EBITDA
-
EV/Sales
3.00
Quick Ratio
2.30
Current Ratio
2.33
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.52
EPS next Y
-0.03
EPS next Q
-0.35
EPS this Y
-122.99%
EPS next Y
94.79%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
-17.24% 18.76%
EPS Y/Y TTM
-158.19%
Sales Y/Y TTM
-61.64%
EPS Q/Q
-153.98%
Sales Q/Q
-76.30%
Insider Own
4.97%
Insider Trans
0.00%
Inst Own
65.21%
Inst Trans
0.26%
ROA
-21.62%
ROE
-
ROIC
-241.68%
Gross Margin
78.65%
Oper. Margin
-28.82%
Profit Margin
-59.87%
SMA20
-10.12%
SMA50
-3.63%
SMA200
8.45%
Trades
Shs Outstand
164.82M
Shs Float
156.76M
52W High
13.39 -24.69%
52W Low
6.20 62.58%
Volatility
7.48% 10.09%
ATR (14)
0.87
RSI (14)
44.88
Beta
2.65
Rel Volume
0.65
Avg Volume
6.27M
Volume
4,061,779
Perf Week
3.92%
Perf Month
-4.91%
Perf Quarter
36.03%
Perf Half Y
25.37%
Perf YTD
50.00%
Perf Year
19.57%
Perf 3Y
54.60%
Perf 5Y
-93.23%
Perf 10Y
-65.00%
Prev Close
10.47
Price
10.08
Change %
-3.72%
Consensus
Buy
Avg. Price Target
$15.29
Implied Upside
+51.7%
Analysts10incl. previous ratings
Rating Distribution5 Buy · 2 Hold · 3 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 24, 2025Resumed
CCantor Fitzgerald
Overweight$18+78.6%
Aug 28, 2025Resumed
HH.C. Wainwright
Buy$10-0.8%
Aug 20, 2025Downgrade
BAC logoBBofA Securities
Neutral → Underperform$7-30.6%
Jun 17, 2025Initiated
C logoCCitigroup
Sell$6-40.5%
Feb 28, 2025Initiated
BBTIG Research
Buy$19+88.5%
Jul 30, 2024Downgrade
JPM logoJJP Morgan
Neutral → Underweight$8-20.6%
May 10, 2024Upgrade
JPM logoJJP Morgan
Underweight → Neutral
May 10, 2024Upgrade
BAC logoBBofA Securities
Underperform → Neutral$4 → $12+19.0%
Aug 09, 2023Upgrade
RILY logoRB. Riley Securities
Neutral → Buy$15+48.8%
Apr 20, 2023Downgrade
TD logoTTD Cowen
Outperform → Market Perform$55 → $10-0.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ruxandra Draghia AkliFormer OfficerMay 27 '26Proposed Sale11.0121,383235,412May 27 04:42 PM
Ruxandra Draghia AkliFormer OfficerMay 07 '26Proposed Sale9.8730,000296,083May 07 05:03 PM
Newton Charles W.DirectorApr 25 '26Option Exercise0.009,52009,520Apr 28 05:00 PM
Shiver John W.DirectorMar 10 '26Option Exercise0.007,94707,947Mar 12 05:00 PM
Kelly James PatrickEVP, CFO and TreasurerMar 07 '26Option Exercise0.0012,2230136,503Mar 09 06:13 PM
Kelly James PatrickEVP, CFO and TreasurerMar 03 '26Option Exercise0.0043,1670145,130Mar 05 06:04 AM
Jacobs John CPresident and CEOMar 03 '26Option Exercise0.00150,1670264,130Mar 05 06:03 AM
O'Hara ElaineEVP, Chief Strategy OfficerMar 03 '26Option Exercise0.0056,3340157,071Mar 05 06:02 AM
Casey Mark JEVP, Chief Legal OfficerMar 03 '26Option Exercise0.0037,5000101,445Mar 05 06:01 AM
Draghia-Akli RuxandraEVP, Research & DevelopmentMar 03 '26Option Exercise0.0026,667034,876Mar 05 06:00 AM
Jacobs John CPresident and CEOMar 01 '26Option Exercise0.0083,3330264,130Mar 03 09:37 PM
Kelly James PatrickEVP, CFO and TreasurerMar 01 '26Option Exercise0.0058,6660130,299Mar 03 09:35 PM
O'Hara ElaineEVP, Chief Strategy OfficerMar 01 '26Option Exercise0.0059,6000111,706Mar 03 09:34 PM
Casey Mark JEVP, Chief Legal OfficerMar 01 '26Option Exercise0.004,000065,159Mar 03 09:33 PM
Jacobs John CPresident and CEOJan 23 '26Option Exercise0.0083,1970219,929Jan 26 07:57 PM
Casey Mark JEVP, Chief Legal OfficerDec 11 '25Option Exercise0.0041,899073,972Dec 15 04:01 PM
Draghia-Akli RuxandraSection 16Nov 11 '25Option Exercise0.0014,257014,257Nov 13 05:23 PM
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
PresidentMr. John Charles Jacobs M.B.A.
Executive VPMr. James Patrick Kelly C.F.A.
J.D.Mr. Mark J. Casey Esq.
Executive VP & Chief Strategy OfficerMs. Elaine O'Hara
Executive VP & COOMr. Richard P. Crowley